The results of a prospective comparative study on the efficacy and safety of the dietary supplement «Nephrobac»® in the complex treatment of patients with chronic pyelonephritis.

Introduction. Chronic pyelonephritis is the most common kidney disease. In accordance with chronic nature of infection, an important aspect treatment recurrent uncomplicated urinary tract infections antibiotic resistance. The aim this work to evaluate dynamics number relapses and severity symptoms against background complex drug «Nephrobac»®. Materials methods. study included 60 patients aged 24 56 years complaints pain in lumbar area, fever, dysuria. Based on examination, were diagnosed pyelonephritis. randomized into two groups: first group received only antibacterial therapy, second therapy combination biologically active «Nephrobac»® 1 capsule 2 times a day for month. Patients both groups observed 6 months from start therapy. Results. Fewer cases leukocyturia receiving «Nephrobac»®, 45% 75% after 3 months, respectively. addition, same group, there significantly fewer bacteriuria visits main compared control There no registered including three relapse each group. Conclusions. can be recommended as part pyelonephritis, which has anti-relapse anti-inflammatory effect, enhancing antibiotics.